Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)

NCT02393859 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

111

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia, Acute Lymphoblastic

Interventions

DRUG: Blinatumomab
DRUG: Dexamethasone
DRUG: Vincrisitne
DRUG: Daunorubicin
DRUG: Methotrexate
DRUG: Ifosfamide
DRUG: PEG-asparaginase
DRUG: Erwinia-asparaginase

Sponsor

Amgen